top of page
resisttb

Relief in South Africa after J&J reversal allows key tuberculosis drug production at lower prices

Johnson and Johnson successfully applied for a patent extension on bedaquiline; however, in a big win for LMI countries, the company has decided not to enforce its patent, allowing generic producers to manufacture the drug. Additionally, J&J has reduced the price of bedaquiline for South Africa by around 40%, making it more affordable for the country. J&J’s reversal of its past decisions regarding bedaquiline was prompted by an investigation of the company’s pricing policies led by the South African government. Learn more here.

23 views0 comments

Recent Posts

See All

Comments


bottom of page